Compare BFS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | ANNX |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.9M | 730.4M |
| IPO Year | N/A | 2020 |
| Metric | BFS | ANNX |
|---|---|---|
| Price | $33.54 | $5.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 54.7K | ★ 2.2M |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ 42.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.16 | $1.29 |
| 52 Week High | $36.51 | $7.18 |
| Indicator | BFS | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 49.49 |
| Support Level | $32.53 | $4.77 |
| Resistance Level | $35.18 | $5.61 |
| Average True Range (ATR) | 0.88 | 0.35 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 32.43 | 33.89 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.